Lobular Panniculitis After IL-2 Treatment
Author Information
Author(s): J.W. Baars, J.L.L.M. Coenen, J. Wagstaf, P. van der Valk, H.M. Pinedo
Primary Institution: Free University Hospital
Hypothesis
Can subcutaneous administration of IL-2 lead to severe local reactions?
Conclusion
The study reports a case of lobular panniculitis that developed after subcutaneous IL-2 treatment and recurred with intravenous administration.
Supporting Evidence
- IL-2 is registered for treating renal cell carcinoma in Europe.
- Subcutaneous IL-2 is less toxic than intravenous protocols.
- The patient experienced severe local reactions at injection sites.
Takeaway
One patient had a bad reaction to a medicine called IL-2 when it was injected under the skin, and the problem got worse when they tried giving it through an IV.
Methodology
The patient was treated with IL-2 and monitored for side effects, including a biopsy of the affected area.
Limitations
Only one case is reported, limiting generalizability.
Participant Demographics
A 40-year-old woman with metastatic renal cell cancer.
Want to read the original?
Access the complete publication on the publisher's website